top of page
a new modality in oncology
valink therapeutics is rethinking antibody-drug conjugates (ADCs) with a new class: bispecific ADCs (bsADCs). their v-gate™ framework goes beyond incremental tweaks to identify rare biological synergies that boost efficacy, improve tolerability, and expand patient access.
redefining adc discovery
most adc innovation has focused on linkers and payloads. valink takes a different approach: using biology itself to change how drugs work. by harnessing bispecificity as a mechanism of action, v-gate™ powered bsadcs can reach patients conventional adcs often miss and may overcome resistance. founded in 2021 by arne scheu (ceo) and irsyad khairil (cto), valink combines strong roots in biologics and oncology with world-class advisors, including robert lutz. from their hubs in the uk and cambridge, massachusetts, the team is advancing a new generation of complex biologics designed for real-world impact.
related stories
bottom of page